|
1) Ozawa E. Our trails and trials in the subsar-colemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era. Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86: 798-821
|
|
|
|
2) Hoffman EP, Brown RH Jr., Kunkel LM. Dys-trophin: the protein product of the Duchenne mus-cular dystrophy locus. Cell. 1987; 51: 919-28
|
|
|
|
|
|
3) 小澤鍈二郎. ジストロフィン. 東京: 学会出版センター; 1992
|
|
|
|
|
|
4) Yoshida M, Hama H, Ishikawa-Sakurai M, et al. Biochemical evidence for association of dys-trobrevin with the sarcoglycan-sarcospan com-plex as a basis for understanding sarcoglycano-pathy. Hum Mol Genet. 2000; 9: 1033-40
|
|
|
|
|
|
5) Aartsma-Rus A, Fokkema I, Verschuuren J, et al. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat. 2009; 30: 293-9
|
|
|
|
|
|
6) Monaco AP, Bertelson CJ, Liechti-Gallati S, et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988; 2: 90-5
|
|
|
|
|
|
7) Tuffery-Giraud S, Beroud C, Leturcq F, et al. Genotype-phenotype analysis in 2, 405 patients with a dystrophinopathy using the UMD-DMD database: a model of nationwide knowledgebase. Hum Mutat. 2009; 30: 934-45
|
|
|
|
|
|
8) Matsuo M, Masumura T, Nishio H, et al. Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dys-trophin gene of Duchenne muscular dystrophy kobe. J Clin Invest. 1991; 87: 2127-31
|
|
|
|
|
|
9) 青木吉嗣, 武田伸一. デュシェンヌ型筋ジストロフィーに対するエクソンスキップ療法. 生体の科学. 2011; 62: 128-33
|
|
|
|
|
10) Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol. 2009; 65: 667-76
|
|
|
|
|
|
11) Aoki Y, Nakamura A, Yokota T, et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther. 2010; 18: 1995-2005
|
|
|
|
|
|
12) van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007; 357: 2677-86
|
|
|
|
|
|
13) Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009; 8: 918-28
|
|
|
|
|